Literature DB >> 9503590

RNA as a drug target: chemical, modelling, and evolutionary tools.

T Hermann1, E Westhof.   

Abstract

Dramatic technical progress in RNA synthesis and structure determination has allowed several difficulties inherent to the preparation, handling and structural analysis of RNA to be overcome, and this has led to a wealth of information about RNA structure and its relationship with biological function. It is now fully recognized that RNA molecules intervene at all stages of cell life, not only because of key sequence motifs but also because of intricate three-dimensional folds. This realization has promoted RNA to a potential therapeutic target. As in protein motifs recognizing nucleic acids, groups of the molecule interacting with RNA contribute to specific binding through defined hydrogen bonds and van der Waals docking, while other parts contribute to the driving force of binding via less specific electrostatic interactions accompanied by water and ion displacement.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9503590     DOI: 10.1016/s0958-1669(98)80086-4

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  23 in total

1.  Effect of peptidyltransferase inhibitors on ribonuclease P activity from Dictyostelium discoideum. Effect of antibiotics on RNase P.

Authors:  C Stathopoulos; A Tsagla; A Tekos; D Drainas
Journal:  Mol Biol Rep       Date:  2000-06       Impact factor: 2.316

2.  Using pyrene-labeled HIV-1 TAR to measure RNA-small molecule binding.

Authors:  Kenneth F Blount; Yitzhak Tor
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

3.  Analyzing the flexibility of RNA structures by constraint counting.

Authors:  Simone Fulle; Holger Gohlke
Journal:  Biophys J       Date:  2008-02-15       Impact factor: 4.033

4.  Specific binding of Hoechst 33258 to site 1 thymidylate synthase mRNA.

Authors:  J Cho; R R Rando
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

5.  Regulation of the RNA-dependent protein kinase by triple helix formation.

Authors:  M Vuyisich; P A Beal
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

Review 6.  Cancer transcriptome profiling at the juncture of clinical translation.

Authors:  Marcin Cieślik; Arul M Chinnaiyan
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

7.  Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing.

Authors:  Jessica L Childs; Matthew D Disney; Douglas H Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

8.  Selection of small peptides, inhibitors of translation.

Authors:  Beatriz Llano-Sotelo; Dorota Klepacki; Alexander S Mankin
Journal:  J Mol Biol       Date:  2009-07-02       Impact factor: 5.469

9.  Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection.

Authors:  S Sinoy; S M Fayaz; K D Charles; V K Suvanish; Josef P Kapfhammer; G K Rajanikant
Journal:  Mol Neurobiol       Date:  2016-05-21       Impact factor: 5.590

10.  Inhibition of Escherichia coli RNase P by oligonucleotide directed misfolding of RNA.

Authors:  Jessica L Childs; Alex W Poole; Douglas H Turner
Journal:  RNA       Date:  2003-12       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.